Levi & Korsinsky alerts Embecta Corp. investors of a pending securities class action covering purchases between November 25, 2025 and May 4, 2026. The lawsuit alleges management concealed significant share loss concentrated at a single major customer and overall retail channel volume softness for insulin pens and pen needles, while describing the pen needle segment as incredibly resolute and reaffirming full-year guidance. On May 5, 2026, Embecta shares fell 57.8 percent, or $5.35, to $3.90 after the company disclosed massive U.S. revenue shortfalls. The complaint states that pen needle revenue was reduced by approximately $53 million, accounting for 70 percent of a total $75 million guidance cut, with competitive share loss at the single customer driving an estimated $25 million of that reduction. The court has set August 17, 2026 as the deadline to apply for lead plaintiff appointment.
Embecta CorpEmbecta disclosed massive U.S. revenue shortfalls due to competitive share loss at a single major customer and overall retail channel volume softness for insulin pens and pen needles.